MOLOGEN AG at a glance

MOLOGEN AG is a biotechnology company specializing in the clinical development of innovative drugs in the fields of oncology and infectious diseases.

The cancer immunotherapy lefitolimod (MGN1703) is the company’s lead product and best-in-class TLR9 agonist. Treatment with lefitolimod (MGN1703) triggers a broad and strong activation of the immune system. Due to this mode of action, namely to reactivate the monitoring function of the immune system, lefitolimod (MGN1703) can be recognized as an Immune Surveillance Reactivator (ISR). It has the potential to be applied to various indications. ISR lefitolimod (MGN1703) is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore, it is also being investigated in an extended phase I study in HIV and a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy®). Next to checkpoint inhibitors, lefitolimod is one of the few product candidates that are in a phase III clinical trial (IMPALA) in the field of immuno-oncology and close to reaching the market.

MOLOGEN AG was founded in 1998 and was one of the first biotechnology companies in Germany to be listed on the stock exchange immediately after its foundation. MOLOGEN AG shares (ISIN DE0006637200) are listed in the Prime Standard on the Frankfurt Stock Exchange.

Around 60 employees are currently working at the company's headquarters in Berlin on the further development of our modern drug candidates.

MOLOGEN’s pipeline focus is on new, innovative immunotherapies to treat diseases for which there is a high medical need.